Publications by authors named "Savita Nandal"
Immune thrombocytopenia (ITP) may occur in isolation (primary) or in association with a predisposing condition (secondary ITP [sITP]). Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health records.
View Article and Find Full Text PDFPurpose: Patients with sickle cell disease (SCD) may experience sickle cell-related pain crises, also referred to as vaso-occlusive crises (VOCs), which are a substantial cause of morbidity and mortality. The study explored how VOC frequency and severity impacts health-related quality of life (HRQoL) and work productivity.
Methods: Three hundred and three adults with SCD who completed an online survey were included in the analysis.
Article Synopsis
- Sickle cell disease (SCD) is a serious chronic condition that significantly impacts quality of life due to painful crises, prompting the need for effective patient-reported outcome (PRO) instruments to evaluate treatments.
- A systematic literature review analyzed studies from 1997 to 2017, identifying 24 validated PRO instruments, but found that many lacked specific validation for SCD populations.
- The findings highlight a limited understanding of the psychometric properties of these instruments and underscore the need for better tools to facilitate future SCD clinical trials in the U.S.
Article Synopsis
- The study aimed to examine how well patients adhered to and persisted with deferasirox film-coated tablets (DFX-FCT) compared to deferasirox dispersible tablets (DFX-DT) after switching, focusing on various diseases, including sickle cell disease, thalassemia, and myelodysplastic syndrome.
- Researchers analyzed data from 606 patients, measuring medication adherence through metrics like medication possession ratio (MPR) and proportion of days covered (PDC) to compare both tablet forms.
- Results showed significant improvements in adherence and persistence for DFX-FCT over DFX-DT, with all disease groups benefiting, especially those with myelodysplastic syndrome (MDS
Pharmacoproteomics is the study of disease-modifying and toxicity parameters associated with therapeutic drug administration, using analysis of quantitative and temporal changes to specific, predetermined, and select proteins, or to the proteome as a whole. Pharmacoproteomics is a rapidly evolving field, with progress in analytic technologies enabling processing of complex interactions of large number of unique proteins and effective use in clinical trials. Nevertheless, our analysis of clinicaltrials.
View Article and Find Full Text PDF